Patent · US Active

Inhibitors of EGFR and methods of use thereof

US10385019B2 · kind B2 · utility

2Cited by
0References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 30, 2016
Grant dateAug 20, 2019
Priority date
Expiry dateJun 30, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D513/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The disclosure relates to a compound having Formula (I′): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.